AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11053174 — intervention group
Group type: EXPERIMENTAL
Intervention: Community based intervention (n=72)
Number of subjects: 141
Study 11053174 — intervention group
Group type: COMPARATOR
Intervention: Hospital based intervention (n=69)
Number of subjects: 141
Study 9117183 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular methotrexate (MTX)
Number of subjects: 21
Study 9117183 — intervention group
Group type: COMPARATOR
Intervention: Oral methotrexate (MTX)
Number of subjects: 21
Study 8449126 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologic concentration of SCFAs
Number of subjects: 14
Study 8449126 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 14
Study 8449126 — intervention group
Group type: EXPERIMENTAL
Intervention: Total SCFA concentration after IPAA
Number of subjects: 14
Study 8449126 — intervention group
Group type: EXPERIMENTAL
Intervention: Stool frequency
Number of subjects: 14
Study 2887188 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 0
Study 2887188 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 20 mg
Number of subjects: 0
Study 2887188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31601123 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary parent training program (Poly Kids)
Number of subjects: 218
Study 29277358 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopy-guided manual lymph drainage (MLD)
Number of subjects: 201
Study 29277358 — intervention group
Group type: COMPARATOR
Intervention: Traditional 'blind' MLD
Number of subjects: 201
Study 29277358 — intervention group
Group type: COMPARATOR
Intervention: Placebo MLD
Number of subjects: 201
Study 27340112 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram + internet-delivered cognitive-behavioural therapy (ICBT)
Number of subjects: 48
Study 27340112 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram + ICBT
Number of subjects: 48
Study 27340112 — intervention group
Group type: COMPARATOR
Intervention: Placebo + ICBT
Number of subjects: 48
Study 23989498 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal aerobic and strength exercises (TG)
Number of subjects: 48
Study 23989498 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy (CG)
Number of subjects: 48
Study 23173250 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhubarb + Pantoprazole
Number of subjects: 107
Study 23173250 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole
Number of subjects: 107
Study 23173250 — intervention group
Group type: COMPARATOR
Intervention: Control group (AMI patients without HF)
Number of subjects: 107
Study 20595543 — intervention group
Group type: EXPERIMENTAL
Intervention: β1‐adrenoreceptor blocker (atenolol; βB) 0.2 mg/kg
Number of subjects: 11
Study 20595543 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (PL)
Number of subjects: 11
Study 20595543 — intervention group
Group type: COMPARATOR
Intervention: Hyperthermia-PL
Number of subjects: 11
Study 20595543 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermia-βB
Number of subjects: 11
Study 18046056 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 6 mg/kg
Number of subjects: 22
Study 18046056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 15651559 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII) with insulin lispro
Number of subjects: 7
Study 12402765 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelox (400 mg/day for 10 days)
Number of subjects: 63
Study 12402765 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin (200 mg twice a day for 10 days)
Number of subjects: 63
Study 7995328 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 0
Study 7995328 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 0
Study 7995328 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine and Saline
Number of subjects: 0
Study 2980291 — intervention group
Group type: EXPERIMENTAL
Intervention: CR-capsules (controlled release)
Number of subjects: 11
Study 2980291 — intervention group
Group type: COMPARATOR
Intervention: Unixan tablets
Number of subjects: 11
Study 31838407 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-C30 in early breast cancer (EBC)
Number of subjects: 5521
Study 31838407 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-C30 in metastatic breast cancer (MBC)
Number of subjects: 5521
Study 31838407 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of poor performance status (PS) and comorbidities in MBC
Number of subjects: 5521
Study 31838407 — intervention group
Group type: COMPARATOR
Intervention: Comparison of HRQoL scores across age and countries
Number of subjects: 5521
Study 30760336 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to UK dietary guidelines (DG)
Number of subjects: 161
Study 30760336 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional UK diet)
Number of subjects: 161
Study 28931976 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling
Number of subjects: 34
Study 28931976 — intervention group
Group type: COMPARATOR
Intervention: Classical physiotherapy program (home exercise, hot pack, TENS, ultrasound)
Number of subjects: 34
Study 25982544 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin (80 mg) once daily
Number of subjects: 142
Study 25982544 — intervention group
Group type: COMPARATOR
Intervention: placebo once daily
Number of subjects: 142
Study 23773343 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-face scale preceded by a yes-no question
Number of subjects: 184
Study 23773343 — intervention group
Group type: COMPARATOR
Intervention: Faces Pain Scale-Revised
Number of subjects: 184
Study 21515905 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental rehearsal of upper limb movements during 45-min supervised sessions three times a week and structured independent sessions twice a week
Number of subjects: 121
Study 21515905 — intervention group
Group type: COMPARATOR
Intervention: Non-motor mental rehearsal (control group)
Number of subjects: 121
Study 21515905 — intervention group
Group type: COMPARATOR
Intervention: Normal care without additional training (control group)
Number of subjects: 121
Study 19368503 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplements (200 microg of selenomethionine)
Number of subjects: 915
Study 16886974 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (TGB) 20-30 mg/day
Number of subjects: 105
Study 16886974 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) 400-800 mg/day
Number of subjects: 105
Study 16886974 — intervention group
Group type: COMPARATOR
Intervention: No-drug group (untreated patients)
Number of subjects: 105
Study 14993550 — intervention group
Group type: EXPERIMENTAL
Intervention: Early inhaled nitric oxide (iNO) therapy
Number of subjects: 299
Study 14993550 — intervention group
Group type: COMPARATOR
Intervention: Simulated initiation of iNO (control)
Number of subjects: 299
Study 11317659 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood-glucose control with metformin (n = 342)
Number of subjects: 753
Study 11317659 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy primarily with diet (n = 411)
Number of subjects: 753
Study 9135180 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 234
Study 9135180 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil
Number of subjects: 234
Study 8107555 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen administered intragastrically in a single dose of 1.0 g.
Number of subjects: 42
Study 8107555 — intervention group
Group type: COMPARATOR
Intervention: Control group (free from occupational exposure).
Number of subjects: 42
Study 2904424 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized hysteroscopic insemination (SHIFT)
Number of subjects: 40
Study 2904424 — intervention group
Group type: COMPARATOR
Intervention: Non-SHIFT synchronized cycles
Number of subjects: 40
Study 2904424 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic insemination procedure
Number of subjects: 40
Study 2904424 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular stimulation protocol
Number of subjects: 40
Study 4699272 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program for nurse practitioners
Number of subjects: 14
Study 4699272 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional office nurses)
Number of subjects: 14
Study 31926063 — intervention group
Group type: EXPERIMENTAL
Intervention: BioBase mobile app and paired wearable device (BioBeam) used daily for 4 weeks
Number of subjects: 0
Study 31926063 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study 29068800 — intervention group
Group type: EXPERIMENTAL
Intervention: R0 resection margin (>1 mm)
Number of subjects: 1151
Study 29068800 — intervention group
Group type: EXPERIMENTAL
Intervention: R1 resection margin (<1 mm)
Number of subjects: 1151
Study 29068800 — intervention group
Group type: EXPERIMENTAL
Intervention: R1 direct positive margins
Number of subjects: 1151
Study 29068800 — intervention group
Group type: EXPERIMENTAL
Intervention: R1 direct positive resection margin status
Number of subjects: 1151
Study 29068800 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive lymph node status
Number of subjects: 1151
Study 29068800 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO performance status ≥1
Number of subjects: 1151
Study 29068800 — intervention group
Group type: EXPERIMENTAL
Intervention: R1 direct positive superior mesenteric/medial margin resection status
Number of subjects: 1151
Study 29068800 — intervention group
Group type: EXPERIMENTAL
Intervention: R1 direct tumor margins, poor tumor differentiation, positive lymph node status, WHO performance status ≥1, maximum tumor size, and R1 direct posterior resection margin
Number of subjects: 1151
Study 28688704 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic hypo-responders to CRT-D
Number of subjects: 534
Study 28688704 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical hypo-responders to CRT-D
Number of subjects: 534
Study 25956233 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait-assistance robot (GAR) assisted gait training (GAGT)
Number of subjects: 26
Study 25956233 — intervention group
Group type: COMPARATOR
Intervention: Overground conventional gait training (OCGT)
Number of subjects: 26
Study 23817682 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT-guided biopsy (group B: 120 kv; 10 mA; thickness, 2.0 mm; pitch, 23 mm/rot)
Number of subjects: 90
Study 23817682 — intervention group
Group type: COMPARATOR
Intervention: Conventional CT-guided biopsy (group A: 120 kv; 200 mA; thickness, 2.0 mm; pitch, 16 mm/rot)
Number of subjects: 90
Study 23817682 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT-guided biopsy
Number of subjects: 90
Study 23817682 — intervention group
Group type: COMPARATOR
Intervention: Conventional CT-guided biopsy
Number of subjects: 90
Study 22045831 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC; 50 mg/kg by 4 hours followed by 100 mg/kg/d for 48 hours diluted in 5% glucose) and deferoxamine (DFX; at a single dose of 1000 mg diluted in 5% glucose)
Number of subjects: 30
Study 22045831 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) plus deferoxamine (DFX)
Number of subjects: 30
Study 22045831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 19745592 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine (200 mg flat dose on days 1 + 2, repeated at day 28 or upon recovery of neutrophils)
Number of subjects: 22
Study 17261096 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 144
Study 17261096 — intervention group
Group type: COMPARATOR
Intervention: Minimal acupuncture
Number of subjects: 144
Study 15371808 — intervention group
Group type: EXPERIMENTAL
Intervention: LMX (lidocaine 4%) applied 45 minutes before meatotomy
Number of subjects: 52
Study 15371808 — intervention group
Group type: EXPERIMENTAL
Intervention: LMX (lidocaine 4%) applied 30 minutes before meatotomy
Number of subjects: 52
Study 15371808 — intervention group
Group type: COMPARATOR
Intervention: EMLA (lidocaine 2.5% and prilocaine 2.5%) applied 45 minutes before meatotomy
Number of subjects: 52
Study 15371808 — intervention group
Group type: COMPARATOR
Intervention: EMLA (lidocaine 2.5% and prilocaine 2.5%) applied 30 minutes before meatotomy
Number of subjects: 52
Study 11428852 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin treatment
Number of subjects: 3525
Study 11428852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3525
Study 9742282 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Number of subjects: 20
Study 9742282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8113060 — intervention group
Group type: EXPERIMENTAL
Intervention: Process evaluation information collection in a school-based multicenter trial
Number of subjects: 96
Study 3416618 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered melatonin
Number of subjects: 0
Study 3416618 — intervention group
Group type: COMPARATOR
Intervention: Bright light exposure (to suppress serum melatonin levels)
Number of subjects: 0
Study 30717691 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower range group (LRG) 0.8‐1.4 mmol/L or 2.5‐4.3 mg/dL
Number of subjects: 104
Study 30717691 — intervention group
Group type: COMPARATOR
Intervention: Higher range group (HRG) 1.8‐2.4 mmol/L or 5.6‐7.4 mg/dL
Number of subjects: 104
Study 30717691 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 104
Study 29288172 — intervention group
Group type: EXPERIMENTAL
Intervention: eSano BackCare‐D
Number of subjects: 210
Study 29288172 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 210
Study 26427912 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety sensitivity intervention
Number of subjects: 82
Study 26427912 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 82
Study 24364175 — intervention group
Group type: EXPERIMENTAL
Intervention: MGCSH mixed with PRP (test group)
Number of subjects: 14
Study 24364175 — intervention group
Group type: COMPARATOR
Intervention: Collagen resorbable plug (control group)
Number of subjects: 14
Study 24364175 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (test and control)
Number of subjects: 14
Study 21975926 — intervention group
Group type: EXPERIMENTAL
Intervention: Platycodi radix extract standardized to 414 mg of platycodin D
Number of subjects: 5
Study 21975926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 17921065 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline
Number of subjects: 338
Study 17921065 — intervention group
Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 338
Study 17290690 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D vision
Number of subjects: 224
Study 17290690 — intervention group
Group type: COMPARATOR
Intervention: 2D vision
Number of subjects: 224
Study 12661753 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir 500 mg once daily for 16 weeks
Number of subjects: 98
Study 12661753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 10738954 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontingent reinforcer delivery (NCR) with high-preference stimulus
Number of subjects: 1
Study 10738954 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontingent reinforcer delivery (NCR) with low-preference stimulus
Number of subjects: 1
Study 8959469 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruletide (2.5 micrograms)
Number of subjects: 32
Study 8959469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 8959469 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruletide
Number of subjects: 32
Study 1524743 — intervention group
Group type: EXPERIMENTAL
Intervention: Plax prebrushing mouthrinse
Number of subjects: 149
Study 1524743 — intervention group
Group type: COMPARATOR
Intervention: Control rinse
Number of subjects: 149
Study 3928508 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg Voltaren (diclofenac-sodium) before surgery and then 50 mg 3 times a day for 5 days
Number of subjects: 190
Study 3928508 — intervention group
Group type: COMPARATOR
Intervention: Fixed combination tablets (acetylsalicylic acid 500 mg, caffeine 50 mg, aprobarbital 20 mg, codeine phosphate 10 mg) in the highest recommended dose, 2 tablets when needed at most 3 times a day
Number of subjects: 190
Study 31279647 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioplasty plus routine stenting
Number of subjects: 88
Study 31279647 — intervention group
Group type: COMPARATOR
Intervention: Angioplasty only
Number of subjects: 88
Study 29141477 — intervention group
Group type: EXPERIMENTAL
Intervention: Referrals containing information on low SES
Number of subjects: 107
Study 29141477 — intervention group
Group type: COMPARATOR
Intervention: Referrals without information on low SES
Number of subjects: 107
Study 26639943 — intervention group
Group type: EXPERIMENTAL
Intervention: Luseogliflozin 2.5 mg once daily with normal-carbohydrate diet (NCD)
Number of subjects: 18
Study 26639943 — intervention group
Group type: EXPERIMENTAL
Intervention: Luseogliflozin 2.5 mg once daily with low-carbohydrate diet (LCD)
Number of subjects: 18
Study 26639943 — intervention group
Group type: COMPARATOR
Intervention: Placebo with normal-carbohydrate diet (NCD)
Number of subjects: 18
Study 26639943 — intervention group
Group type: COMPARATOR
Intervention: Placebo with low-carbohydrate diet (LCD)
Number of subjects: 18
Study 24581393 — intervention group
Group type: COMPARATOR
Intervention: Induction chemotherapy followed by external beam radiotherapy (EBRT) with concomitant cisplatin (Arm A)
Number of subjects: 274
Study 24581393 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by EBRT with concomitant cisplatin plus brachytherapy boost (Arm B)
Number of subjects: 274
Study 24581393 — intervention group
Group type: COMPARATOR
Intervention: Induction chemotherapy followed by EBRT with concomitant cisplatin (Arm A)
Number of subjects: 274
Study 22933542 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D(3), 50,000 IU monthly (n = 102)
Number of subjects: 203
Study 22933542 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 101)
Number of subjects: 203
Study 20051890 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 83
Study 20051890 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost
Number of subjects: 83
Study 20051890 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost
Number of subjects: 83
Study 20051890 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 83
Study 18085909 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention
Number of subjects: 0
Study 15013324 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac)
Number of subjects: 35
Study 15013324 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine microemulsion (CsA)
Number of subjects: 35
Study 11576201 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (300 to 1200 mg per day)
Number of subjects: 52
Study 11576201 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (serum levels >50 microg/mL)
Number of subjects: 52
Study 9819872 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate 5 mg-patches
Number of subjects: 40
Study 9819872 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 40
Study 7664505 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (2.5 mg twice daily)
Number of subjects: 30
Study 7664505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2712434 — intervention group
Group type: EXPERIMENTAL
Intervention: NO2 exposure (2 ppm)
Number of subjects: 152
Study 2712434 — intervention group
Group type: EXPERIMENTAL
Intervention: NO2 exposure (3 ppm)
Number of subjects: 152
Study 2712434 — intervention group
Group type: EXPERIMENTAL
Intervention: NO2 exposure (1 ppm)
Number of subjects: 152
Study 2712434 — intervention group
Group type: COMPARATOR
Intervention: Clean air (control)
Number of subjects: 152
Study 320670 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical clotrimazole
Number of subjects: 66
Study 320670 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 66
Study 31801502 — intervention group
Group type: EXPERIMENTAL
Intervention: EndExam group (exam at the end of the BLS training)
Number of subjects: 464
Study 31801502 — intervention group
Group type: EXPERIMENTAL
Intervention: 3mExam group (exam 3 months after the BLS training)
Number of subjects: 464
Study 31801502 — intervention group
Group type: COMPARATOR
Intervention: NoExam group (no exam)
Number of subjects: 464
Study 28244635 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin 5 mg once daily for 26 weeks
Number of subjects: 45
Study 28244635 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 45
Study 26135706 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methylprednisolone 1000 mg once a day for 3 days
Number of subjects: 199
Study 26135706 — intervention group
Group type: COMPARATOR
Intervention: Intravenous methylprednisolone 1000 mg once a day for 3 days
Number of subjects: 199
Study 26135706 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methylprednisolone
Number of subjects: 199
Study 26135706 — intervention group
Group type: COMPARATOR
Intervention: Intravenous methylprednisolone
Number of subjects: 199
Study 23880625 — intervention group
Group type: EXPERIMENTAL
Intervention: B lactis + GOS/FOS (10 colony-forming units/g + 0.4 g/100 mL)
Number of subjects: 528
Study 23880625 — intervention group
Group type: COMPARATOR
Intervention: B lactis (10⁷ colony-forming units/g)
Number of subjects: 528
Study 23880625 — intervention group
Group type: EXPERIMENTAL
Intervention: B lactis + GOS/FOS
Number of subjects: 528
Study 23880625 — intervention group
Group type: COMPARATOR
Intervention: B lactis
Number of subjects: 528
Study 21842019 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrush age at 4 weeks
Number of subjects: 110
Study 21842019 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrush age at 8 weeks
Number of subjects: 110